October 2008 in “Journal of Intellectual Property Law & Practice” The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.
February 2023 in “Reactions Weekly”
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib significantly improves hair regrowth in severe alopecia areata.
3 citations
,
November 1998 in “PubMed” September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
January 2021 in “International Journal of Advanced Research in Medicine” Propranolol, flunarizine, and divalproex sodium are equally effective for preventing migraines, but have different side effects.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
101 citations
,
August 2008 in “Mayo Clinic Proceedings” PAD is common but often missed, needing lifestyle changes and medication for better outcomes.
September 2023 in “Journal of the American Academy of Dermatology”
9 citations
,
March 1989 in “The BMJ” Adding diltiazem to a beta blocker can cause dangerously slow heart rates.
January 2026 in “Elsevier eBooks”
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
November 2003 in “PubMed” October 2024 in “BMJ Case Reports” Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly” February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
15 citations
,
January 2000 in “Japanese Heart Journal” A man developed heart problems after using a baldness treatment for 4 months, suggesting that people with heart issues should avoid this treatment.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
September 2003 in “Reactions Weekly” November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
June 2013 in “Annals of the rheumatic diseases” Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
January 2026 in “Rinsho Shinkeigaku” Finasteride and minoxidil may increase stroke risk by affecting blood clotting and blood pressure.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
May 2025 in “The Journal of Rheumatology” Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”